Valued at $2.8bn, the project entailed an unusual combination and integration of financing sources to succeed. The firm represented the underwriters in the $615m private activity bond of this transaction, which was part of a sequence of US-based project financings to re-establish the credibility of private-public partnerships
With mergers and acquisitions activity slowing, biotech companies began entering strategic alliances to fund research and development. Representing OncoMed, the firm structured an alliance with Bayer as an option-based agreement, which involved an upfront payment of $40m to OncoMed and long-term flexibility for both sides
